ArticleJournal of translational medicine2025
Human collagen III mRNA therapy for effective skin rejuvenation.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- mRNA Therapeutics for Skin Rejuvenation: From Aging Atlases to Clinical Translation.Experimental dermatology · 2026Review
- Oral whole-leaf matcha partially attenuates UV-induced dermoepidermal disruption and collagen phenotype alterations in a rat model of repeated photoaging.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSkin photoaging leads to the deterioration of dermal collagen and overall skin integrity, resulting in visible signs of aging, particularly around the eye. Collagen III plays a pivotal role in maintaining skin elasticity and facilitating proper collagen fibril organization. Messenger RNA (mRNA)-based therapeutics present a novel alternative for addressing these limitations by enabling the localized production of full-length, biologically active proteins.
methodsThis study evaluates the therapeutic effects of human collagen III (hCOL3A1) mRNA on UVB-induced skin photoaging using in vitro and in vivo models. In vitro, human fibroblasts were used to assess oxidative stress, senescence, apoptosis, proliferation, and migration. In vivo, a UVB-induced murine photoaging model was used to assess skin barrier function, dermal thickness, collagen content, and senescence markers were analyzed post-treatment. Transcriptome analysis was conducted to explore gene expression changes and key pathways involved in photoaging and repair mechanisms.
resultsOur findings demonstrate that hCOL3A1 mRNA reduces oxidative stress, senescence, apoptosis and promotes cell proliferation and migration in a photoaging cell model. In a murine photoaging model, hCOL3A1 mRNA significantly improves skin barrier function, enhances dermal thickness, restores collagen content, improves dermal structure, and reduces cellular senescence markers without inducing systemic toxicity or immunogenicity. Transcriptome analyses reveal that hCOL3A1 mRNA reverses UVB-induced gene expression changes, reinstating critical signaling pathways for skin homeostasis and fibroblast function.
conclusionsThese results highlight hCOL3A1 mRNA as a promising therapeutic candidate for skin photoaging and underscore the potential of mRNA-based therapies in dermatology and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.